In that report by Dai et al., the authors pooled various GLP-1 receptor agonists with different pharmacology properties into one group and found that GLP-1 receptor agonists were associated with a reduced risk of endometrial cancer and ovarian cancer [141]. Here, GLP1R is linked to ovarian cancer.